Skip to main content

Developmental Delay

0
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
Internet-delivered Parent-Child Interaction TherapyN/A1 trial
Mirror Neuron Network Dysfunction as an Early Biomarker of Neurodevelopmental DisorderN/A1 trial
Active Trials
NCT03260816Completed150Est. Dec 2020
NCT03307317Recruiting200Est. Feb 2031
CENTOGENE
CENTOGENEGermany - Rostock
1 program
Biomarker for Sly Disease (MPS VII) (BioSly)N/A1 trial
Active Trials
NCT02298699Withdrawn0Est. Feb 2021
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Bright By ThreeN/A1 trial
Active Trials
NCT02717390Terminated100Est. Mar 2019
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
H3 ServicesN/A1 trial
Active Trials
NCT02699814Completed277Est. Mar 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Human BioSciencesMirror Neuron Network Dysfunction as an Early Biomarker of Neurodevelopmental Disorder
CENTOGENEBiomarker for Sly Disease (MPS VII) (BioSly)
Colorado TherapeuticsBright By Three
Human BioSciencesInternet-delivered Parent-Child Interaction Therapy
Angeles TherapeuticsH3 Services

Clinical Trials (5)

Total enrollment: 727 patients across 5 trials

NCT03307317Human BioSciencesMirror Neuron Network Dysfunction as an Early Biomarker of Neurodevelopmental Disorder

Mirror Neuron Network Dysfunction as an Early Biomarker of Neurodevelopmental Disorder

Start: Aug 2018Est. completion: Feb 2031200 patients
N/ARecruiting
NCT02298699CENTOGENEBiomarker for Sly Disease (MPS VII) (BioSly)

Biomarker for Sly Disease (MPS VII) (BioSly)

Start: Aug 2018Est. completion: Feb 20210
N/AWithdrawn
NCT02717390Colorado TherapeuticsBright By Three

Bright by Three (BB3) Effectiveness Study

Start: Aug 2017Est. completion: Mar 2019100 patients
N/ATerminated
NCT03260816Human BioSciencesInternet-delivered Parent-Child Interaction Therapy

Advancing Child Competencies by Extending Supported Services (ACCESS) for Families Program

Start: Mar 2016Est. completion: Dec 2020150 patients
N/ACompleted
NCT02699814Angeles TherapeuticsH3 Services

H3: Healthy Minds, Healthy Children, Healthy Chicago Project Evaluation

Start: Mar 2016Est. completion: Mar 2019277 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 727 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.